GlassScriptPhysician profile
Gerald Thomas Pruitt
NPI 1356399232
$3,100.61
in general payments reported to CMS, 2019-2025
25 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.53 · 2020: $76.91 · 2021: $57.61 · 2022: $210 · 2023: $513 · 2024: $603 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $925.03 | 2020-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.87 | 2020-2025 | Ofev, Stiolto Respimat, Jascayd |
| Verona Pharma, INC. | $205.88 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $196.98 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $192.68 | 2024-2025 | |
| Insmed, INC. | $178.78 | 2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $158.13 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $117.68 | 2024-2025 | Dupixent |
| Electromed, INC. | $93.62 | 2024-2025 | Smartvest |
| Amgen INC. | $89.19 | 2025 | Tezspire |
| Pulmonx Corporation | $88.68 | 2021-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $81.27 | 2023-2025 | Glassia |
| Viatris Specialty LLC | $74.63 | 2025 | Yupelri |
| Baxter Healthcare | $62.40 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $42.08 | 2024-2025 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $41.59 | 2022-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $37.34 | 2023-2025 | Zerbaxa |
| Allergan, INC. | $24.82 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.18 | 2025 | |
| Novo Nordisk INC | $20.79 | 2025 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $17.26 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.96 | 2025 | |
| Lilly USA, LLC | $15.39 | 2025 | Mounjaro, Zepbound |
| Abbvie INC. | $14.67 | 2022 | |
| Melinta Therapeutics, LLC | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Pruitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.